Kowa

WOKINGHAM, England, August 17, 2010 - Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK licence for their statin, Livazo(R) (pitavastatin).

WOKINGHAM, England, April 28, 2010 - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP* and EAS* low-density lipoprotein cholesterol (LDL-C) targets at 52 weeks, respectively.

BARCELONA, Spain - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers.

BARCELONA, Spain - - Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to atorvastatin and simvastatin at usual therapeutic doses in patients with primary hypercholesterolemia or combined dyslipidemia, as measured by reduction of low density lipoprotein cholesterol (LDL-C) from baseline.

BOSTON - Pitavastatin Represents Important Treatment Option for More Vulnerable Populations New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidaemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin.